Undisclosed Program (AMD)
Age-Related Macular Degeneration
Pre-clinical / ClinicalIn pipeline; uses ADS Platform
Key Facts
Indication
Age-Related Macular Degeneration
Phase
Pre-clinical / Clinical
Status
In pipeline; uses ADS Platform
Company
About Cloudbreak Pharmaceutical
Founded in 2015 and headquartered in Irvine, California, Cloudbreak Pharmaceutical is a global biotech focused on transforming ophthalmic care through innovative drug development. The company has advanced its lead asset, CBT-001, into Phase 3 trials following a successful End-of-Phase 2 meeting with the FDA, positioning it as a potential first therapeutic for pterygium. Cloudbreak's strategy combines in-house R&D expertise with strategic regional partnerships, including agreements with Santen and Grand Pharma, to develop and commercialize its pipeline across major markets.
View full company profileTherapeutic Areas
Other Age-Related Macular Degeneration Drugs
| Drug | Company | Phase |
|---|---|---|
| hOTX2 | BrainEver | Discovery |
| DARC for AMD | Novai | Exploratory Biomarker in Clinical Studies |
| Undisclosed AMD Program | Mobius Scientific | Preclinical |
| iPSC-derived RPE cells | Healios | Preclinical/Research |